KALA Quote, Financials, Valuation and Earnings

Quince Therapeutics, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of --. Kala Bio, Inc.'s return on equity of -1375.54% beat Quince Therapeutics, Inc.'s return on equity of -267.62%.

Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 781.32%. On the other hand Quince Therapeutics, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -100%. Given that Kala Bio, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Kala Bio, Inc. is more attractive than Quince Therapeutics, Inc..

Kala Bio, Inc. has a beta of -1.980, which suggesting that the stock is 298.018% less volatile than S&P 500. In comparison Quince Therapeutics, Inc. has a beta of 1.334, suggesting its more volatile than the S&P 500 by 33.435%.

Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quince Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Quince Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kala Bio, Inc. quarterly revenues are --, which are smaller than Quince Therapeutics, Inc. quarterly revenues of --. Kala Bio, Inc.'s net income of -$7.6M is higher than Quince Therapeutics, Inc.'s net income of -$13.4M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Quince Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus -- for Quince Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scienture Holdings, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of -611.42%. Kala Bio, Inc.'s return on equity of -1375.54% beat Scienture Holdings, Inc.'s return on equity of -24.88%.

Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 781.32%. On the other hand Scienture Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 406.24%. Given that Kala Bio, Inc. has higher upside potential than Scienture Holdings, Inc., analysts believe Kala Bio, Inc. is more attractive than Scienture Holdings, Inc..

Kala Bio, Inc. has a beta of -1.980, which suggesting that the stock is 298.018% less volatile than S&P 500. In comparison Scienture Holdings, Inc. has a beta of 3.160, suggesting its more volatile than the S&P 500 by 215.993%.

Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scienture Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.50 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Scienture Holdings, Inc. pays out 81.44% of its earnings as a dividend. Scienture Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kala Bio, Inc. quarterly revenues are --, which are smaller than Scienture Holdings, Inc. quarterly revenues of $590K. Kala Bio, Inc.'s net income of -$7.6M is lower than Scienture Holdings, Inc.'s net income of -$3.6M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Scienture Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 5.81x for Scienture Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sonida Senior Living, Inc. has a net margin of -- compared to Kala Bio, Inc.'s net margin of -30.87%. Kala Bio, Inc.'s return on equity of -1375.54% beat Sonida Senior Living, Inc.'s return on equity of -72.2%.

Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 781.32%. On the other hand Sonida Senior Living, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 5.66%. Given that Kala Bio, Inc. has higher upside potential than Sonida Senior Living, Inc., analysts believe Kala Bio, Inc. is more attractive than Sonida Senior Living, Inc..

Kala Bio, Inc. has a beta of -1.980, which suggesting that the stock is 298.018% less volatile than S&P 500. In comparison Sonida Senior Living, Inc. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.381%.

Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonida Senior Living, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. Sonida Senior Living, Inc. pays out 85.92% of its earnings as a dividend. Sonida Senior Living, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kala Bio, Inc. quarterly revenues are --, which are smaller than Sonida Senior Living, Inc. quarterly revenues of $97.7M. Kala Bio, Inc.'s net income of -$7.6M is higher than Sonida Senior Living, Inc.'s net income of -$30.1M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while Sonida Senior Living, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 1.53x for Sonida Senior Living, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx Corp. has a net margin of -- compared to Kala Bio, Inc.'s net margin of -185.96%. Kala Bio, Inc.'s return on equity of -1375.54% beat SCWorx Corp.'s return on equity of -74.77%.

Kala Bio, Inc. has a consensus price target of $1.50, signalling upside risk potential of 781.32%. On the other hand SCWorx Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kala Bio, Inc. has higher upside potential than SCWorx Corp., analysts believe Kala Bio, Inc. is more attractive than SCWorx Corp..

Kala Bio, Inc. has a beta of -1.980, which suggesting that the stock is 298.018% less volatile than S&P 500. In comparison SCWorx Corp. has a beta of 2.264, suggesting its more volatile than the S&P 500 by 126.384%.

Kala Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kala Bio, Inc. pays -- of its earnings as a dividend. SCWorx Corp. pays out -- of its earnings as a dividend.

Kala Bio, Inc. quarterly revenues are --, which are smaller than SCWorx Corp. quarterly revenues of $705.8K. Kala Bio, Inc.'s net income of -$7.6M is lower than SCWorx Corp.'s net income of -$1.3M. Notably, Kala Bio, Inc.'s price-to-earnings ratio is -- while SCWorx Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kala Bio, Inc. is 7.18x versus 0.32x for SCWorx Corp.. Usually stocks with elevated PS ratios are considered overvalued.